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Multiple myeloma, a cancer of the antibody-generating plasma 
cells, is the second most common hematological malignancy. 
In this disease, myeloma cells proliferate in the bone marrow, 
leading to decreased blood cell formation and bone resorption 
locally and causing systemic disease (especially renal failure) 
through their production of large amounts of abnormal immuno-
globins. The proteasome inhibitor bortezomib is now part of the 
preferred treatment for multiple myeloma (Raab et al., 2009; 
Goldberg, 2011), and >400,000 patients worldwide have now 
received the drug, which has over two billion dollars in annual 
sales. Most importantly, this agent has led to major improvements 
in disease management and increased the lifespan of patients by 
years. Also, new combinations with other drugs are continually 
being introduced that are proving more effective and have fewer 
side effects. Recently, a second proteasome inhibitor, carfil-
zomib, has also received Food and Drug Administration (FDA) 
approval (Siegel et al., 2012), and three others are in clinical   
trials primarily for treating myeloma (Kisselev et al., 2012). 
Bortezomib is also approved for mantle cell lymphoma, and trials 
against other conditions are now in progress, including other 
cancers and inflammatory diseases, and for immunosuppression 
(Kisselev et al., 2012).
Why are myeloma cells particularly sensitive to protea-
some inhibition? This special sensitivity was not anticipated 
and was only discovered during human trials of bortezomib. 
The primary reason is that most of the proteins expressed by 
myeloma cells are abnormal immunoglobins, and a key role 
of the ubiquitin–proteasome pathway is eliminating misfolded, 
potentially toxic proteins (Cenci et al., 2012). In this quality 
control process, termed ER-associated degradation, misfolded 
secretory proteins are extracted from the ER to the cytoplasm 
for degradation by the proteasome (Meusser et al., 2005). This   
process is also very important in the functioning of normal 
plasma  cells  because  immunoglobins  are  large  multisubunit 
molecules with multiple postsynthetic modifications, and many 
steps can go wrong in its synthesis (Cenci et al., 2012). Another 
reason for their special sensitivity is that myeloma cells rely 
on the transcription factor NF-B (Nuclear Factor-B), which 
inhibits apoptosis and promotes expression of growth factors 
and  cytokines  important  for  tumor  pathogenesis  (Hideshima 
et al., 2002). The proteasome activates NF-B primarily by 
degrading its key inhibitor IB. Therefore, treatment with the 
proteasome inhibitors prevents NF-B activation and leads 
to toxic accumulation of misfolded proteins, which activates 
JNK and eventually apoptosis. These key functions of the pro-
teasome that explain bortezomib’s efficacy in myeloma—NF-B 
activation  and  its  role  in  ER-associated  degradation—were 
elucidated through many basic studies that used proteasome 
inhibitors as research tools. In other words, the medical prog-
ress and advances in understanding proteasome biology went 
hand in hand.
The historical background
The development of proteasome inhibitors for treatment of can-
cers has had a curious history that reflects the multiple strands 
of my own research career (Goldberg, 2011). When we initiated 
this research, we were not aiming to find new cancer therapies. 
Instead, our goal was based upon my long-standing interest 
(spanning almost 50 yr) to clarify the mechanisms of muscle 
atrophy, as occurs upon disuse, aging, or disease (e.g., cancer). 
These early experiments demonstrated unexpectedly that the 
rapid loss of muscle protein after denervation or fasting was 
caused primarily by an acceleration of overall protein break-
down rather than a reduction in protein synthesis (Goldberg, 
1969), thereby providing the first evidence that overall rates of 
The proteasome is the primary site for protein degrada-
tion in mammalian cells, and proteasome inhibitors have 
been invaluable tools in clarifying its cellular functions. 
The anticancer agent bortezomib inhibits the major pepti-
dase sites in the proteasome’s 20S core particle. It is a 
“blockbuster drug” that has led to dramatic improvements 
in the treatment of multiple myeloma, a cancer of plasma 
cells. The development of proteasome inhibitors illustrates 
the unpredictability, frustrations, and potential rewards of 
drug development but also emphasizes the dependence of 
medical advances on basic biological research.
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needed to develop a drug. (2) My experience consulting for 
biotechnology companies in the 1980s was a very positive one 
and had illustrated the satisfactions in seeing basic knowledge 
contribute to development of new therapies. Therefore, in the early 
1990s, I convinced a group of Harvard colleagues to help found 
a small company, optimistically named MyoGenics, whose goal 
would be to try to block the debilitating loss of muscle in cancer 
and other diseases (Goldberg, 2011). Eventually, we found a 
venture capital group willing to gamble on this novel disease 
target (muscle wasting) and novel biochemical rationale.
In addition, I had a secret agenda. I realized that specific 
inhibitors of the proteasome could be very valuable tools to 
clarify the physiological functions of the ubiquitin–proteasome 
system in cells. However, this goal was kept secret because venture 
capitalists and business executives were not motivated to ad-
vance biological knowledge. Nevertheless, our success in this 
hidden agenda has proven to be a major legacy of the company 
as the lead compounds that led to bortezomib (e.g., MG132) 
have greatly advanced our understanding of many aspects of 
cell regulation, disease mechanisms, and immune surveillance 
(Rock and Goldberg, 1999). Unlike most companies, MyoGenics 
distributed our first proteasome inhibitors freely to academic   
investigators, whose efforts rapidly advanced our knowledge 
of the proteasome’s importance in cancer, apoptosis, and in-
flammation. In fact, MG132 has now been used as a research 
tool in over four thousand scientific studies because it is potent, 
inexpensive, and reversible.
Although MyoGenics (later renamed ProScript) was short 
lived as a separate entity, it was exceptionally successful in 
its scientific discoveries as well as in drug development. The 
company assembled a small, talented scientific team, including   
enzymologists led by Ross Stein, chemists led by Julian Adams, 
and cell biologists led by Vito Palombella. In addition, it had 
multiple close collaborations with us Harvard-based scientists. 
For example, when the first peptide aldehyde proteasomal in-
hibitors were available, their effects on muscle were analyzed 
(Tawa et al., 1997) in my laboratory and on antigen presentation 
in Kenneth Rock’s (Rock et al., 1994). Company scientists, in   
collaboration with Tom Maniatis’s laboratory, also made im-
portant findings about another key function of the proteasome, 
in the activation of NF-B, the critical transcription factor in 
inflammation and cancer (Palombella et al., 1994; Silverman 
and Maniatis, 2001). This important role of the proteasome   
indicated that proteasome inhibitors could have dramatic effects 
in blocking inflammatory disease (e.g., arthritis) and cancer. 
Therefore, the company’s focus soon evolved to focus on these 
well-established disease targets and changed its name to ProScript 
(from proteasomes and transcription).
Creating proteasome inhibitors
Most cell proteins are marked for degradation by attachment   
of a ubiquitin chain, which leads to their rapid degradation by 
the 26S proteasome, a 60-subunit particle composed of a 20S 
core and one or two 19S regulatory particles. Ubiquitinated pro-
teins bind initially to the 19S particle, which contains enzymes 
to disassemble the ubiquitin chain and a ring of ATPases that 
unfold the protein and translocate it into the 20S proteasome 
protein breakdown in mammalian cells are precisely regulated 
and help determine muscle size.
At the time, in 1969, virtually nothing was known about 
the pathways for protein catabolism in cells, and therefore,   
I decided to focus my research on the biochemical mechanisms 
of protein degradation in addition to exploring physiological 
regulation of this process in muscle (Goldberg and Dice, 1974; 
Goldberg and St John, 1976). Our physiological studies in the 
1970s and 1980s showed that protein breakdown also increases 
and causes muscle wasting during cancer cachexia, sepsis, and 
renal or cardiac failure (Mitch and Goldberg, 1996; Lecker et al., 
1999), whereas our biochemical study demonstrated the exis-
tence of a new, nonlysosomal proteolytic pathway in cells (later 
called the ubiquitin–proteasome system) that requires ATP and 
selectively eliminates misfolded proteins (Etlinger and Goldberg, 
1977). A  fundamental  advance  came  with  the  Nobel  prize 
winning discovery by Hershko, Ciechanover, and Rose of the 
involvement of ATP and the small protein ubiquitin in marking 
proteins for rapid hydrolysis (Hershko and Ciechanover, 1998; 
Glickman and Ciechanover, 2002). This knowledge enabled us, 
in the 1980s, to show that, in mammalian cells, ATP is also 
necessary for the degradation of ubiquitin-conjugated pro-
teins (Tanaka et al., 1983), and in 1987, Rechsteiner’s (Hough 
et al., 1987) and our groups (Waxman et al., 1985) described 
the very large ATP-dependent protease complex that degraded 
ubiquitin-conjugated proteins, which we subsequently named the 
26S proteasome.
The original rationale for generating 
proteasome inhibitors
Eventually, our two research interests in the physiological regu-
lation of muscle protein breakdown and in the biochemical 
mechanism for proteolysis began to interconnect. In the late 
1980s, we showed that the excessive proteolysis responsible 
for muscle wasting in many rodent disease models (e.g., cancers, 
renal failure, or denervation atrophy) was primarily caused by 
an activation of the ubiquitin–proteasome pathway (Mitch and 
Goldberg, 1996; Lecker et al., 1999), which was until then   
believed to degrade only misfolded or regulatory proteins (Hershko 
and Ciechanover, 1998; Glickman and Ciechanover, 2002; 
Goldberg, 2003). In fact, this system also digests long-lived 
proteins that comprise the bulk of cellular proteins. It is now 
clear that atrophying muscles undergo a series of transcriptional 
adaptations involving FoxO transcription factors that enhance 
their capacity for proteolysis (Lecker et al., 2004; Sandri et al., 
2004), including increased expression of ubiquitin and key 
ubiquitination enzymes (Bodine et al., 2001; Gomes et al., 
2001). These insights led me to propose that it could be beneficial 
to a large number of patients to pharmacologically inhibit this 
degradative process in muscle.
Starting a biotech company and my  
secret agenda
I decided to found a biotech company to inhibit proteasome 
function for two reasons: (1) There was no mechanism within 
the university to bring together a group of scientists with the   
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modifications in the peptide backbone then generated bortezo-
mib within months.
The 20S proteasome was subsequently found to have a 
unique proteolytic mechanism, through the x-ray crystallographic 
studies of Huber and Baumeister (Voges et al., 1999; Kisselev 
and Goldberg, 2001; Borissenko and Groll, 2007; Kisselev et al., 
2012), the active sites use the hydroxyl group of the N-terminal 
threonine residues to attack peptide bonds. Bortezomib and the 
peptide aldehyde inhibitors form adducts with this threonine 
that mimic the transition state intermediate during peptide 
cleavage (Fig. 2). A key early finding was that blocking the pro-
teasome did not immediately kill cells or prevent normal func-
tion (Rock et al., 1994; Tawa et al., 1997). My prime concern 
had been that proteasome inhibition would be very toxic, caus-
ing accumulation of misfolded or regulatory proteins in ubiq-
uitinated forms. In fact, compared with typical chemotherapeutic 
agents, proteasome inhibitors are not very toxic. The pres-
ence in cells of many enzymes that disassemble ubiquitin con-
jugates and recycle the ubiquitin meant that, upon proteasome 
inhibition, only a small fraction of cell proteins accumulate as 
ubiquitin conjugates form. Therefore, cells could function well 
for many hours or days with reduced proteasomal capacity.   
Furthermore, bortezomib and the other proteasome inhibitors 
block primarily the chymotrypsin-like sites, leaving the other sites 
functional. Thus, at therapeutic doses, bortezomib probably   
inhibits protein degradation for hours at most by only 20–30% 
(Kisselev et al., 2006), which does not perturb most cells signif-
icantly. However, myeloma cells are susceptible to this degree 
of inhibition because of their very high rates of breakdown   
of abnormal immunoglobulins, which are continually being 
cleared by the ubiquitin–proteasome system (Cenci et al., 2012). 
(Pickart and Cohen, 2004; Finley, 2009; Peth et al., 2010).   
Degradation occurs within this hollow, cylindrical particle con-
sisting of four stacked rings (Fig. 1). The outer rings contain seven 
distinct but homologous  subunits, and the inner rings contain 
seven homologous  subunits (Coux et al., 1996; Baumeister   
et al., 1998; Voges et al., 1999; Borissenko and Groll, 2007). Three 
 subunits contain the proteolytic sites, which face the inner 
chamber of the cylinder. In each  ring, there is a chymotrypsin-
like, a trypsin-like, and a caspase-like site (Fig. 1), which act 
synergistically to cleave proteins to small peptides.
The first proteasome inhibitors synthesized were simple 
peptide aldehydes (Rock et al., 1994; Lee and Goldberg, 1998; 
Kisselev and Goldberg, 2001), which were analogues of the 
preferred substrates of the proteasome’s chymotrypsin-like   
active site. These inhibitors were not obtained through random 
screening of huge chemical libraries but instead were initially 
synthesized based on our knowledge of the substrate specificity 
of the proteasome’s active sites. Although the proteasome’s 
architecture and enzymatic mechanisms were unknown at the 
time, it was clear that the chymotrypsin-like site is the most 
important one in protein breakdown (Coux et al., 1996; Voges   
et al., 1999), and we knew that small hydrophobic peptides 
could often penetrate cell membranes. Therefore, the C termini 
of hydrophobic peptide substrates were derivatized to form 
peptide aldehydes, which were known to be effective inhibi-
tors of serine and cysteine proteases. (Thus, MG132 is, in fact, 
simply carbobenzyl-Leu-Leu-Leu-aldehyde; Fig. 2). This com-
pound was the lead molecule in medicinal chemistry efforts led 
by Julian Adams to enhance potency, selectivity, and stability. 
In place of the aldehyde (Fig. 2), he introduced the critical boro-
nate “warhead,” which increased its potency 50–100-fold, and 
Figure 1.  Structure and function of the 26S proteasome. (A) Structure and components of the 26S proteasome. For more accurate images, see Lander   
et al. (2012) and Lasker et al. (2012). (B) Location of active sites in the 20S proteasome core. There are three types of proteolytic sites in the 20S prote-
asome’s central chamber, and each  ring contains three active sites. Bortezomib and MG132 act primarily on the chymotrypsin-like site in the  subunit 
but also inhibit the caspase-like site at high concentrations.JCB • VOLUME 199 • NUMBER 4 • 2012   586
(Instead, it heralded the purchase of seven drug candidates—all 
of which failed on the way to clinic.)
Through these troubled times, the core team of ProScript 
scientists continued working on bortezomib’s actions and phar-
macology. Their efforts, led by Julian Adams (Adams et al., 
1999), continued to generate evidence of bortezomib’s prom-
ise, and through his advocacy, it was given greater emphasis as   
Millennium’s other programs faltered. The promise of bor-
tezomib against cancer received valuable support from screens 
against various tumor xenografts at the National Cancer Institute, 
and Millennium eventually initiated clinical trials against all 
human cancers.
Because  of  the  financial  challenges  and  unwarranted 
fears about its toxicity, bortezomib development was almost 
terminated several times before its success in the clinic could 
be established. The eventual dramatic success of bortezomib in 
the clinic has come as a real surprise to the industry and to the 
cancer community. I am certain that many other valuable treat-
ments may have been terminated inappropriately for the lack 
of talented advocates, sufficient investment, or expert design   
of clinical trials, and their potential for helping patients were 
never realized.
Bortezomib’s clinical development is also a tale of ser-
endipity. When it entered phase I trials against all cancers, 
one treated patient showed a complete remission. That patient 
had multiple myeloma, in which there had been no precedent 
for such dramatic improvement. Because some additional clear   
responses were evident in myeloma patients for whom there 
was no adequate therapy, phase II trials focused on this dis-
ease. They were performed by the team of Ken Anderson and 
Paul Richardson of the Dana-Farber Cancer Institute in an   
efficient and expert manner, which led to FDA approval after 
only phase II trials, as a result of the clear benefits found (Raab 
et al., 2009). Although initially approved for use only when 
Consequently, even mild inhibition of the proteasome in these 
cells causes toxic accumulation of abnormal proteins, and trig-
gers apoptosis, especially when they are weakened by NF-B 
depletion. It is important to note that the 19S regulatory complex 
contains many other subunits and enzymatic activities, which 
comprise additional possible targets for drug development.
Bortezomib’s tribulations and  
surprising success
Only a few years have passed from our finding that protea-
some inhibitors could reduce intracellular proteolysis (Rock   
et al., 1994), to the synthesis of bortezomib, to the acquisition of 
evidence for efficacy against cancer in mouse models (Adams   
et al., 1999), which came largely from screening at the National   
Cancer Institute. Despite this rapid progress, at multiple junc-
tures, its development came close several times to termination 
for financial reasons (Goldberg, 2011). Our initial corporate 
partner decided not to pursue proteasome inhibitors in the 
clinic, and no other pharmaceutical company was interested in 
gambling on bortezomib becoming a drug, despite the impres-
sive preclinical data. Because investment in the biotechnology 
industry had dried up at the time, our investors decided to sell 
ProScript to a larger company, Leukocyte, owned by the same 
group. Perhaps the best indication of how poorly bortezomib 
was valued by the “experts” is that the company’s assets (i.e., 
bortezomib and promising related research) were sold for less 
than three million dollars. In contrast, sales of bortezomib this 
year were almost 1,000 times the cost of the entire company. 
Leukocyte was soon purchased by Millennium Pharmaceuti-
cals, a larger company that had failed to generate drug candi-
dates. Initially, Millennium also failed to evaluate this program 
highly and even failed to announce its purchase of bortezomib, 
the one program that eventually led to its dramatic growth. 
Figure 2.  Structure and mechanism of action of proteasome inhibitors. (A) Structure of MG132, an inhibitor widely used in uncovering many cellular 
functions of the proteasome. (B and C) Structure of bortezomib (B), the inhibitor used to treat multiple myeloma, and its chemical reaction with the active 
site terminal threonine residue of the 5 subunit (C). (D) The primary mechanisms by which bortezomib causes death of myeloma cells.587 Development of proteasome inhibitors • Goldberg
Academic investigators certainly do not need to compromise 
their ideals when working with profit-driven companies to de-
velop agents that benefit suffering patients. Such collaborations 
should be fostered and can certainly be rewarding and fun!
The paths to scientific advances and the medi-
cal benefits of basic research are often unpredict-
able.  I  never  anticipated  that  our  early  observations  on  the 
mechanisms of muscle wasting might somehow contribute to 
therapies for multiple myeloma. In fact, had I ever suggested such 
outcomes in a grant proposal, the reviewers would have rejected 
such statements as ridiculous, fanciful, or naive and instead sup-
ported less innovative, more traditional lines of investigation.
Probably, the greatest rewards that a life in 
biological  research  can  provide  are  seeing  one’s 
work lead to both a greater understanding of living 
systems and to improvements in medical care. Hav-
ing focused for >40 yr on the mechanisms of intracellular pro-
tein  breakdown  and  for  25  yr  on  understanding  proteasome 
function, I have been fortunate to enjoy both rewards. It has 
been particularly gratifying to contribute to the development of 
the proteasome inhibitor bortezomib/velcade, which has had a 
major impact on the treatment of many patients. However, it has 
also been highly rewarding to witness the enormous advances in 
our knowledge about cell regulation, immune surveillance, and 
human disease that have been made using proteasome inhibitors 
as research tools.
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